Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
mTOR Signaling in Disease and Therapy
share announcement

mTOR Signaling in Disease and Therapy

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 31 January 2025 | Viewed by 2780

Special Issue Editors

Dr. Wenjing Yu

E-Mail Website
Guest Editor
Department of Orthodontics, University of Pennsylvania School of Dental Medicine, Philadelphia, PA 19104, USA
Interests: dental
Dr. Chider Chen

E-Mail Website
Guest Editor
Department of Oral and Maxillofacial Surgery/Pharmacology, University of Pennsylvania School of Dental Medicine, Philadelphia, PA, USA
Interests: craniofacial; oral; dental; tissue engineering
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The mammalian target of rapamycin (mTOR) signaling is an indispensable kinase cascade which regulates the development and homeostasis of mammalian tissues through multiple biological mechanisms. mTOR works with other components to form distinct protein complex 1 (mTORC1) and complex 2 (mTORC2) functions as a regulator of cell growth, cell mobility, cell survival, autophagy, protein synthesis, and gene transcription. In this regard, as the dysregulation of mTOR signaling is implicated in the pathogenesis of many human diseases, targeting mTOR signaling is a unique therapeutic approach for disease management.  

We are pleased to invite you to submit your work on mTOR-mediated pathogenesis and the mechanisms of diseases, translational medical research targeting mTOR signaling, and drug discovery based on mTOR cascades. This Special Issue invites basic, preclinical, and translational advances in the diagnosis and treatment of mTOR-related disorders. Original research articles, reviews, and case reports illustrating unique clinical care within the scope of mTOR signaling are welcome. Research areas of interest include, but are not limited to, the following: bone metabolism, craniofacial and oral disorders, stem cells, novel targets in various therapeutic areas, cell/gene/target therapy, and oncology.

We look forward to receiving your contributions.

Dr. Wenjing Yu
Dr. Chider Chen
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mTOR signaling
  • tissue engineering
  • stem cell
  • disease
  • therapy
  • bone
  • craniofacial
  • biomedicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

16 pages, 1265 KiB  
Review
The Role of mTOR in Mycobacterium tuberculosis Infection
by Ami Patel, Lannhi Nguyen, Christina Shea, Sunjum Singh and Vishwanath Venketaraman
Biomedicines 2024, 12(10), 2238; https://doi.org/10.3390/biomedicines12102238 - 1 Oct 2024
Viewed by 901
Abstract
Background/Objectives: Mycobacterium tuberculosis (M. tb) is a pathogen that causes tuberculosis (TB), an extremely infectious disease which is responsible for millions of deaths worldwide. The severity of this pathogen is further amplified with the emergence of multidrug-resistant strains that are [...] Read more.
Background/Objectives: Mycobacterium tuberculosis (M. tb) is a pathogen that causes tuberculosis (TB), an extremely infectious disease which is responsible for millions of deaths worldwide. The severity of this pathogen is further amplified with the emergence of multidrug-resistant strains that are becoming more prevalent at an alarming rate, and novel treatments are needed. Methods: In this paper, we discuss the pathology M. tb infection. We review the literature on the role that mTOR plays in autophagy and the immune system as well as its impact on M. tb infection. Lastly, we discuss the current therapies targeting mTOR and potential routes to explore for future treatments. Results: The mTOR protein acts as a negative regulator of the autophagy pathway and presents as a potent target to establish new treatments for TB. M. tb survival is affected by mTOR, the PI3K/mTOR/AKT pathway, and autophagy. M. tb evades destruction by manipulating host cellular mechanisms, which increases resistance and complicates treatment. Conclusions: Targeting mTOR can enhance autophagy and increase M. tb clearance. Existing drugs such as everolimus, rapamycin + CC214-2, and bazedoxifene are all being currently studied for effectiveness and show positive results. Alternative therapies, including Chinese herbs, baicalin, BTLA, glutathione, and precision medicine can modulate the PI3K/mTOR/AKT pathway and the host’s immune response, resulting in increased M. tb clearance, and these may be the future treatments for M. tb infection. Full article
(This article belongs to the Special Issue mTOR Signaling in Disease and Therapy)
►▼ Show Figures

Figure 1

18 pages, 1364 KiB  
Review
The Role of the PI3K/Akt/mTOR Axis in Head and Neck Squamous Cell Carcinoma
by Qian Jiang, Jingyi Xiao, Yao-Ching Hsieh, Neha Love Kumar, Lei Han, Yuntao Zou and Huang Li
Biomedicines 2024, 12(7), 1610; https://doi.org/10.3390/biomedicines12071610 - 19 Jul 2024
Viewed by 1299
Abstract
Head and neck squamous cell carcinoma (HNSCC) is one of the most common malignancies globally, representing a significant public health problem with a poor prognosis. The development of efficient therapeutic strategies for HNSCC prevention and treatment is urgently needed. The PI3K/AKT/mTOR (PAM) signaling [...] Read more.
Head and neck squamous cell carcinoma (HNSCC) is one of the most common malignancies globally, representing a significant public health problem with a poor prognosis. The development of efficient therapeutic strategies for HNSCC prevention and treatment is urgently needed. The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved transduction network in eukaryotic cells that promotes cell survival, growth, and cycle progression. Dysfunction in components of this pathway, such as hyperactivity of PI3K, loss of PTEN function, and gain-of-function mutations in AKT, are well-known drivers of treatment resistance and disease progression in cancer. In this review, we discuss the major mutations and dysregulations in the PAM signaling pathway in HNSCC. We highlight the results of clinical trials involving inhibitors targeting the PAM signaling pathway as a strategy for treating HNSCC. Additionally, we examine the primary mechanisms of resistance to drugs targeting the PAM pathway and potential therapeutic strategies. Full article
(This article belongs to the Special Issue mTOR Signaling in Disease and Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop